Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ningxin Shugan
- Development stage
- Unknown
- Lead developer
- Shuguang Hospital
- Administration
- Oral
01
Overview
Ningxin Shugan is a Traditional Chinese Medicine (TCM) granule formulation developed by Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically designed to treat elderly patients suffering from hypertension comorbid with anxiety and depression. The name reflects its therapeutic principles in TCM: "Ningxin" (calming the heart) and "Shugan" (soothing the liver). It is currently being evaluated in clinical trials to determine its efficacy in improving blood pressure control and psychological well-being, as well as to elucidate its underlying biological mechanisms.
- Other names
- Ningxin Shugan granule
Beyond the preview
Go deeper on Ningxin Shugan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningxin Shugan.